BioXcel Therapeutics (BTAI)
(Delayed Data from NSDQ)
$0.62 USD
-0.02 (-3.18%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $0.62 +0.01 (0.81%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Industry / Sector Report
Industry : Medical - Biomedical and Genetics
Zacks Industry Rank
Top 33% (83 out of 251)Zacks Sector Rank
Top 25% (4 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 2.00 | 1.37 | 9.99 |
Current Quarter Estimate | -0.45 | 2.92 | 61.00 |
Year Ago Quarter Estimate | -1.72 | -4.86 | 54.84 |
Next Quarter Estimate | -0.37 | 3.90 | 63.00 |
Next Year Estimate | -1.45 | 25.15 | 275.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 70.08 | 18.00 | 15.67 |
Next Year | 21.20 | 9.30 | 11.34 |
Last 5 Years | NA | 0.90 | 8.10 |
Next 5 Years | 41.80 | 21.60 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -6.80 |
Price/Book (MRQ) | NA | 2.09 |
Price/Cash Flow (MRFY) | NA | 17.39 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | -4,487.39% | -147.72% |
Return on Equity (TTM) | NA | -60.38% |
Debt to Equity (MRQ) | -1.39 | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.